EARS - Auris Medical Holding Ltd.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.5400
+0.0100 (+0.65%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.5300
Open1.5100
Bid1.5100 x 1000
Ask1.6000 x 1200
Day's Range1.4800 - 1.5600
52 Week Range1.3000 - 9.2000
Volume145,123
Avg. Volume143,591
Market Cap5.086M
Beta (5Y Monthly)-0.33
PE Ratio (TTM)N/A
EPS (TTM)-1.3270
Earnings DateMar 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.18
  • Should You Take Comfort From Insider Transactions At Auris Medical Holding Ltd. (NASDAQ:EARS)?
    Simply Wall St.

    Should You Take Comfort From Insider Transactions At Auris Medical Holding Ltd. (NASDAQ:EARS)?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

  • GlobeNewswire

    Auris Medical Announces Notice of Allowance for European Patent Application

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the European Patent Office (EPO) has issued a notice of “Intention to Grant” for its patent application entitled “Treatment of Tinnitus Through Modulation of Chloride Co-Transporter NKCC1 in the Auditory System” (European Patent Application 11 894 529.3). The communication from the EPO concludes substantive examination of the patent application, which is now expected to issue as a patent once the issue fees are paid and the patent office concludes its respective administrative procedures. A corresponding patent application is currently pending before the US Patent and Trademark Office (USPTO) and was already granted in Japan.

  • GlobeNewswire

    Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a new subsidiary, Zilentin Ltd., to bundle its development projects for the treatment of tinnitus and hearing loss in a separate entity. Upon completion of the transfers from other Group companies, Zilentin AG shall own all tangible and intangible assets related to the development of tinnitus therapeutics (Keyzilen® / AM-101 as well as early stage projects) and hearing loss therapeutics (Sonsuvi® / AM-111). Zilentin Ltd. is domiciled in Zug, Switzerland.

  • Do Institutions Own Auris Medical Holding Ltd. (NASDAQ:EARS) Shares?
    Simply Wall St.

    Do Institutions Own Auris Medical Holding Ltd. (NASDAQ:EARS) Shares?

    A look at the shareholders of Auris Medical Holding Ltd. (NASDAQ:EARS) can tell us which group is most powerful...

  • GlobeNewswire

    Auris Medical Announces Positive Interim Results from AM-201 Phase 1b Study in Antipsychotic-Induced Weight Gain

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced positive interim results from its Phase 1b trial with AM-201 in antipsychotic-induced weight gain and somnolence. The study demonstrated good safety and tolerability of AM-201 over the four-week treatment period and revealed relevant reductions in olanzapine-induced weight gain and daytime sleepiness. In female study participants, who overall showed more pronounced changes than male participants, a reduction in weight gain of 1.1 kg against placebo was observed at the highest tested dose of 20 mg three times per day (probability of effectiveness = 90%).

  • GlobeNewswire

    Auris Medical Receives FDA and EMA Guidance for Keyzilen® Late-Stage Clinical Development Program

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that it has obtained advice on the development plan and regulatory pathway for its investigational tinnitus treatment Keyzilen® (AM-101) from the U.S. Food and Drug Administration (“FDA”) and from the European Medicines Agency (“EMA”). The Company had reached out to the two agencies in order to discuss and validate the design of a new Phase 2/3 trial for the Keyzilen® program. In their feedback, both the FDA and EMA supported the use of the Tinnitus Functional Index (TFI) questionnaire as the primary efficacy outcome measure.

  • GlobeNewswire

    Auris Medical Announces Notices of Allowance for U.S. and European Patent Applications Covering Intranasal Betahistine

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for its patent application entitled “Pharmaceutical Composition Comprising Betahistine” (U.S. Patent Application No. 15/887,388). In addition, the Company received an “Intention to Grant” notice from the European Patent Office (EPO) for its related patent application entitled “Intranasal Composition Comprising Betahistine” (European Patent Application 18 703 749.4).

  • GlobeNewswire

    Auris Medical Announces Appointment of New Chief Financial Officer

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the appointment of Elmar Schärli, CPA, as new Chief Financial Officer, effective November 1, 2019. “We’d like to thank Hernan for his years of service and many contributions to Auris, and we wish him all the best in his new position.” Hernan Levett will be staying with Auris Medical through October 31 to ensure a smooth transition. Elmar Schärli has acquired almost 30 years of both private and public company finance and accounting experience in the biotech and medtech industry.

  • GlobeNewswire

    Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a Scientific Advisory Board (SAB) for its tinnitus research and development programs. “We are delighted to have several world-renowned tinnitus experts join Auris Medical as advisors as we are preparing to advance our various tinnitus projects through further clinical and pre-clinical development,” stated Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “There continues to be a strong unmet medical need amongst tinnitus sufferers worldwide, and we look forward to bringing novel therapeutics to patients.

  • New Strong Sell Stocks for August 23rd
    Zacks

    New Strong Sell Stocks for August 23rd

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • GlobeNewswire

    Auris Medical Provides Business Update and Reports First Half 2019 Financial Results

    Hamilton, Bermuda, Aug. 15, 2019 -- Enrollment of first patient in TRAVERS Phase 2 trial with AM-125 in acute vertigoEnrollment completed in Phase 1b trial with AM-201 in.

  • GlobeNewswire

    Auris Medical Announces Randomization of First Patient in AM-125 Phase 2 Trial in Acute Vertigo

    The TRAVERS trial will enroll a total of 138 patients who suffer from acute vertigo following surgical removal of a vestibular schwannoma, a tumor growing behind the inner ear. In addition, oral betahistine 48 mg will be tested in 16 patients under open-label conditions for reference. “After securing approvals from the numerous regulatory authorities and ethics committees involved, we are excited to start patient enrollment into the TRAVERS trial,” commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO.

  • GlobeNewswire

    Auris Medical Completes Enrollment of Phase 1b Proof-Of-Concept Trial of AM-201 in Antipsychotic-Induced Weight Gain

    The trial enrolled in total 50 healthy volunteers who received either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks. “Completing enrollment for this proof-of-concept study is another important step forward with our AM-201 development program,” commented Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “Excessive weight gain and somnolence are major side effects of antipsychotic drugs that frequently have a major impact on patient well-being and quality of life.

  • Savara Plunges on Failure of Late-Stage Study on Molgradex
    Zacks

    Savara Plunges on Failure of Late-Stage Study on Molgradex

    Savara's (SVRA) lead pipeline candidate, Molgradex, fails to meet primary endpoint in a phase III study evaluating it in a rare autoimmune lung disorder.

  • GlobeNewswire

    Auris Medical Holding Ltd Provides Corporate Update

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today provided a business update, including a review of recent clinical, regulatory and operational highlights and progress. “In the past few months, we continued to make substantial progress with our intranasal betahistine development program, moving into two proof-of-concept studies,” stated Thomas Meyer, Auris Medical’s founder, Chairman and CEO.

  • GlobeNewswire

    Auris Medical Holding Ltd Regains Compliance with Nasdaq Minimum Bid Price Rule

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders (the “Company”), announced today that it has received written notification from the Nasdaq Hearings Panel (the “Panel”) notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (“Nasdaq”).. The Panel determined that the Company is in compliance with all applicable Nasdaq listing standards, that its common shares will continue to be listed on Nasdaq and that the Panel considers this matter closed. Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care.

  • GlobeNewswire

    Auris Medical Announces Closing of Public Offering of Common Shares

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced today the closing of its previously announced underwritten public offering of: (i) 440,000 common shares together with warrants to purchase 440,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares, including 110,000 common shares and warrants to purchase 110,000 common shares sold pursuant to a partial exercise by the underwriters of the underwriters’ over-allotment option. The combined public offering price per unit of one common share and one warrant to purchase one common share is $3.90 and $3.89 per unit of one pre-funded warrant to purchase one common share and one warrant to purchase one common share.

  • GlobeNewswire

    Auris Medical Announces Closing of Two US Patent Acquisitions Related to the Use of Betahistine for the Treatment of Depression and ADHD

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the successful closing of the purchase of two US patents related to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD). The Company acquired full ownership of the US patents 8,119,668 and 8,242,148, “Treatment methods employing histamine H3 receptor antagonists, including betahistine,” with key claims directed towards the treatment of depression and ADHD, respectively.

  • GlobeNewswire

    Auris Medical Holding Ltd.:

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, announced today the pricing of an underwritten public offering of: (i) 330,000 common shares together with warrants to purchase 330,000 common shares, and (ii) 1,721,280 pre-funded warrants, with each pre-funded warrant exercisable for one common share, together with warrants to purchase 1,721,280 common shares. The combined public offering price per common unit is $3.90 and $3.89 per pre-funded unit.  The pre-funded warrants will have an initial per share exercise price of CHF 0.01, are exercisable immediately and will expire when exercised in full.  The common share warrants will have an initial per share exercise price of CHF 4.34, subject to customary adjustment, are exercisable immediately and will expire 5 years from the date of issuance.

  • GlobeNewswire

    Auris Medical Reaches Midpoint for Enrollment in AM-201 Phase 1b Proof-of-Concept Study in Antipsychotic-Induced Weight Gain

    The Phase 1b trial with AM-201 is being conducted at one European site. The trial will enroll in total 50 healthy volunteers who will receive either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks. The protocol is based on a dose escalation with five different doses of intranasal betahistine.

  • GlobeNewswire

    Auris Medical Announces Reverse Stock Split

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that its Board of Directors has approved a reverse stock split of its common shares at a ratio of 1-for-20. The reverse stock split is expected to become effective on May 1, 2019, and the shares to begin trading on the split-adjusted basis on the Nasdaq Capital Market under the Company's existing trading symbol "EARS". The new CUSIP number following the reverse stock split will be G07025201.

  • GlobeNewswire

    Auris Medical Provides Update on Tinnitus Drug Development Strategy

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today provided an update on its tinnitus drug development strategy. The Company intends to discuss and validate the protocol for a pivotal clinical trial with its late-stage investigational drug Keyzilen® (AM-101) with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and to take the program forward through partnering or other types of non-dilutive funding. The Company has completed the design of a new Phase 2/3 trial for its late-stage Keyzilen® program.

  • Benzinga

    Buyer's Remorse? OTC Stock Zoom Technologies Zooms Higher Amid Potential Buyer Confusion

    Zoom Technologies Inc (OTC: ZOOM ) traded higher by as much as 120 percent Thursday morning after popular video and audio platform Zoom Video Communications Inc (NASDAQ: ZM ) held its highly anticipated ...

  • GlobeNewswire

    Auris Medical Receives Positive Nasdaq Listing Determination

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the Nasdaq Hearings Panel (the ''Panel'') has granted the Company’s request for the continued listing of the Company’s securities on The Nasdaq Capital Market (“Nasdaq”). The Company’s continued listing on Nasdaq is subject to the Company evidencing compliance with the minimum $1.00 bid price requirement on or before August 5, 2019. At the hearing before the Panel, the Company presented its plan to regain compliance with the minimum bid price requirement, including the implementation of a reverse stock split if necessary.

  • GlobeNewswire

    Auris Medical Announces Randomization of First Dose Cohort in AM-201 Phase 1b Proof-of-Concept Study

    Auris Medical Holding Ltd. (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced that the first cohort of subjects have been randomized in its Phase 1b proof-of-concept trial of AM-201, the Company's investigational drug for the prevention of antipsychotic-induced weight gain and somnolence. The Phase 1b trial with AM-201 is being conducted at one European site. The trial will enroll in total 50 healthy volunteers who will receive either AM-201 or placebo concomitantly with the antipsychotic drug olanzapine over four weeks.